 |
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
|
Pathogenetix
Raises $1.5M
Pathogenetix Inc. has raised $1.51 million from a $1.81 million equity offering from five investors, according to an SEC filing.
Pathogenetix, formerly named U.S. Genomics, raised $1.3 million and converted $900,000 in debt earlier this year.
CEO John J. Canepa is named in the filing along with directors Augustine Lawlor from Cambridge-based HealthCare Ventures; Stephen Gullans and Enrico Petrillo from Boston-based Excel Venture Management; and David Hoey most recently from InfoLibria, Inc.
Canepa joined Pathogenetix as CFO in 2003. The Board of Directors appointed him to the position of CEO in November 2005. Previously, Canepa served as Vice President, Finance & Administration, and CFO of Winphoria Networks, Inc., a venture capital-backed wireless telecommunications company. Canepa holds a Masters in Finance from Michigan State University and a B.A. from Denison University.
Pathogenetix develops commercial applications of single molecule DNA, RNA and protein analysis. The company's technologies address high value unmet needs in bio-security, human diagnostics, and food and drug contaminant monitoring.
Founded in 1997 and based in Woburn, Massachusetts, Pathogenetix has raised a total of $61 million from HealthCare Ventures, StillRiver Fund, CB Health Ventures, Fidelity Biosciences Group, Zero Stage Capital and private investors. In addition, the company has been awarded Phase I, II and III contracts totaling $39 million by the U.S. Department of Homeland Security Advanced Research Project Agency (HSARPA) and other U.S. Government agencies to develop a sophisticated biological sensor for biodefense applications.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|